CMTM3 Suppresses Proliferation and Osteogenic Transdifferentiation of C2C12 Myoblasts through p53 Upregulation
Cells · 2024
DOI: 10.3390/cells13161352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Enzhao Shen und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Research Institute of Pharmaceutical Sciences, Chonnam National University, Gwangju 61186, Republic of Korea. Hauptthemen laut MEDLINE: Cell Proliferation, Cell Transdifferentiation, Chemokines, MARVEL Domain-Containing Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT), Zhejiang Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
CKLF-like MARVEL transmembrane domain-containing 3 (CMTM3), a member of the CMTM family that is closely related to tumor occurrence and progression, plays crucial roles in the immune system, cardiovascular system, and male reproductive system. Recently, CMTM3 has emerged as a potential target for treating diseases related to bone formation. However, additional studies are needed to understand the mechanisms by which CMTM3 regulates the process of osteogenic differentiation. In this study, we observed a significant downregulation of Cmtm3 expression during the transdifferentiation of C2C12 myoblasts into osteoblasts induced by BMP4. Cmtm3 overexpression suppressed proliferation and osteogenic differentiation in BMP4-induced C2C12 cells, whereas its knockdown conversely facilitated the process. Mechanistically, Cmtm3 overexpression upregulated both the protein and mRNA levels of p53 and p21. Conversely, Cmtm3 knockdown exerted the opposite effects. Additionally, we found that Cmtm3 interacts with p53 and increases protein stability by inhibiting proteasome-mediated ubiquitination and degradation. Notably, Trp53 downregulation abrogated the inhibitory effect of Cmtm3 on BMP4-induced proliferation and osteogenic differentiation of C2C12 myoblasts. Collectively, our findings provide key insights into the role of CMTM3 in regulating myoblast proliferation and transdifferentiation into osteoblasts, highlighting its significance in osteogenesis research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Research Institute of Pharmaceutical Sciences, Chonnam National University, Gwangju 61186, Republic of Korea.
- School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325000, China.
ORCID-Profile: Meiyu Piao, Yuankuan Li, Sung Ho Lee
Förderung
- National Research Foundation of Korea
- National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT)
- Zhejiang Provincial Natural Science Foundation of China
Zitieren
APA
Shen, E., Piao, M., Li, Y., Wu, Y., Li, S., Lee, S. H., Jin, L., & Lee, K. Y. (2024). CMTM3 Suppresses Proliferation and Osteogenic Transdifferentiation of C2C12 Myoblasts through p53 Upregulation. Cells. https://doi.org/10.3390/cells13161352
Vancouver
Shen E, Piao M, Li Y, Wu Y, Li S, Lee SH, et al. CMTM3 Suppresses Proliferation and Osteogenic Transdifferentiation of C2C12 Myoblasts through p53 Upregulation. Cells. 2024. doi:10.3390/cells13161352
BibTeX
@article{Shen2024,
author = {Shen, Enzhao and Piao, Meiyu and Li, Yuankuan and Wu, Yuecheng and Li, Sihang and Lee, Sung Ho and Jin, Litai and Lee, Kwang Youl},
title = {CMTM3 Suppresses Proliferation and Osteogenic Transdifferentiation of C2C12 Myoblasts through p53 Upregulation},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13161352}
}
EUVIMED